Aardvark Therapeutics, Inc. (AARD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.38-6.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AARD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Aardvark plans to provide further guidance on its program in the second quarter of 2026.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Unblind and evaluate totality of efficacy and safety data from Phase 3 HERO and OLE trials to inform future development decisions.
Stated as a priority in 2 of last 2 quarters. Management plans to assess unblinded HERO and OLE trial data in Q3 2026. The trials were terminated in June 2026 and remain paused due to the FDA clinical hold, indicating the assessment is ongoing with no new efficacy or safety data disclosed yet.
“In the third quarter of this year, we are assessing the unblinded data from the HERO and OLE trials to understand efficacy and safety results.”
“Aardvark intends to unblind the clinical data accumulated to date across both the HERO trial and the OLE trial to assess totality of efficacy and safety data.”
Manage cash, cash equivalents, and short-term investments to fund operations through late 2027.
Stated as a priority in 2 of last 2 quarters. Cash and equivalents declined from $91.2 million in 2026-Q1 to $73.9 million in 2026-Q2. Management projects this cash runway to fund operations into late 2027, indicating delivery on maintaining sufficient liquidity despite cash burn.
“Cash, cash equivalents and short-term investments of $73.9 million as of June 30, 2026, supports projected operations into late 2027.”
“Held $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, sufficient to fund operations into mid-2027.”
Commit to updating investors with additional guidance on clinical programs and trial data in the second quarter of 2026.
Provide retention bonuses to CFO, COO, and CMO to maintain leadership stability.
Newly stated in 2026-Q2. Management provided retention bonuses to key executives including CFO, COO, and CMO to maintain leadership stability amid operational challenges. This is a one-time disclosed action with no prior quarters stating this priority.
“The company provided retention bonuses to its CFO/COO and CMO.”
Over the trailing year it converted 0.95x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.